 LOS ANGELES, May 18, 2022 GLOBE NEWSWIRE -- Aadi Bioscience, Inc. Nasdaq: AADI, a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadis executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL. 